Trial site
Hospital HM Nou Delfos
- 31running trials
- 16closed trials
The trials here
What the 48 trials at this site are about, from their registry records.
- Conditions
- Lung cancer24 trials
- Ovarian cancer9 trials
- Gastric and oesophageal cancer8 trials
- Colorectal cancer7 trials
- Pancreatic cancer7 trials
- Head and neck cancer6 trials
- Metastatic breast cancer6 trials
- Liver and biliary tract cancer5 trials
- Bladder cancer4 trials
- Cervical cancer4 trials
- Acute myeloid leukaemia3 trials
- Endometrial cancer3 trials
- and 11 more
- Phase
- Phase 123 trials
- Phase 1/214 trials
- Phase 27 trials
- Phase 31 trial
- Status
- Recruiting21 trials
- Completed15 trials
- Not yet recruiting7 trials
- Active, not recruiting3 trials
- Suspended1 trial
- Terminated1 trial
- Lead sponsor
- Hospital HM Nou Delfos3 trials
- Taiho Oncology, Inc.3 trials
- BioNTech SE2 trials
- EMD Serono Research & Development Institute, Inc.2 trials
- Enliven Therapeutics2 trials
- and 34 more
Running trials
Recruiting
Recruiting
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)
Not yet recruiting
A Phase 2 Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
Recruiting
Recruiting
Recruiting
Recruiting
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Recruiting
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Recruiting
Recruiting
Recruiting
Recruiting
Modulation of the Inflammatory Response in Bariatric Surgery
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
Recruiting
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Recruiting
Recruiting
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Recruiting
Active, not recruiting
Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
Recruiting
Recruiting
Recruiting
Recruiting
Active, not recruiting
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Enrolling by invitation
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Lung cancer10 recruiting
- Ovarian cancer6 recruiting
- Head and neck cancer4 recruiting
- Liver and biliary tract cancer4 recruiting
- Metastatic breast cancer4 recruiting
- Pancreatic cancer4 recruiting
- Acute myeloid leukaemia3 recruiting
- Bladder cancer3 recruiting
- Cervical cancer3 recruiting
- Myelodysplastic syndromes3 recruiting
- Colorectal cancer2 recruiting
- Gastric and oesophageal cancer2 recruiting
- Brain metastases1 recruiting
- Childhood cancers1 recruiting
- Chronic myeloid leukaemia1 recruiting
- Endometrial cancer1 recruiting
- Melanoma1 recruiting
- Mesothelioma1 recruiting
- Neuroendocrine tumours1 recruiting
- Obesity1 recruiting
- Prostate cancer1 recruiting
- Sarcoma1 recruiting
Closed trials
Completed
A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations
Active, not recruiting
Phase 1b/2 Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced NSCLC (Substudy NSCLC)
Completed
Completed
Active, not recruiting
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Active, not recruiting
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Completed
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
Terminated
Terminated
Completed
Active, not recruiting
Active, not recruiting
Completed
Completed
Completed
Comparison of Two Magnesium Sulfate Protocols in Opioid-Free Anesthesia for Bariatric Surgery
Active, not recruiting
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Site data: ClinicalTrials.govUpdated 18 Nov 2026